dalpiciclib + exemestane

Dalpiciclib + exemestane is a combination therapy under investigation primarily for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Dalpiciclib is an oral small-molecule inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), which blocks cell cycle progression in cancer cells by inhibiting phosphorylation of retinoblastoma protein. Exemestane is a steroidal aromatase inhibitor that suppresses estrogen synthesis, thereby reducing tumor growth in estrogen-dependent cancers. The combination leverages dual mechanisms—cell cycle arrest and endocrine suppression—to enhance antitumor efficacy. This regimen has been studied as neoadjuvant therapy and in other settings for HR+/HER2- breast cancer, showing promising objective response rates and manageable safety profiles[1][6][10].